Stay updated with breaking news from Alex Aimetti. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Enrollment complete in Phase 3 TrustTSC trial with topline data anticipated in the first half of Q4 2024 USPTO grants additional method of use patent for ganaxolone in TSC ...
RADNOR, Pa.--(BUSINESS WIRE)--$MRNS #MarinusPharma--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the speakers for its upcoming Investor & Analyst Event on Tuesday, September 19 from 9:00 a.m....
Operator: Greetings and welcome to the Marinus Pharmaceuticals’ First Quarter 2023 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode.